🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 76 of 116

  1. VK-2019

    Cullinan Therapeutics

    Nasopharyngeal Carcinoma

    phase 2 small molecule terminated

    1 trial

  2. VOR33

    Vor Biopharma

    Leukemia, Myeloid, Acute

    phase 2 mab terminated

    1 trial

  3. VS-6766, VS-6063

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 2 small molecule active

    1 trial

  4. VV1

    Regeneron UK Limited

    Melanoma

    phase 2 mab active

    1 trial

  5. VX15/2503 + avelumab

    VACCINEX, INC.

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  6. Vaccine

    Atrium Therapeutics

    Pediatric Cancer

    phase 2 mab active

    1 trial

  7. Valemetostat Tosylate, Golcadomide, RITUXIMAB, Valemetostat Tosylate, Golcadomide, RITUXIMAB, Golcadomide

    Celgene Europe Limited

    Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma

    phase 2 small molecule active

    1 trial

  8. Valemetostat Tosylate, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Valemetostat Tosylate

    Daiichi Sankyo

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    Relapsed/Refractory Peripheral T-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  10. Valemetostat Tosylate, Valemetostat Tosylate

    The George Institute

    Adult patients with histologically/cytologically confirmed progressive metastatic or recurrent solid tumor, who have selected chromatin remodeling deficiency in at least one of the following genes: SMARCB1, SMARCA4, SMARCA2, SMARCC1, SMARCC2, ARID1A, ARID1B, PBRM1, BAP1and other SWI/SNF sub-units; or molecularly (Wildtype) and phenotypically-selected Clear cell endometrial or ovarian carcinoma cancers.

    phase 2 small molecule active

    1 trial

  11. Varnimcabtagene autoleucel, BENDAMUSTINE, FLUDARABINE, DEXCHLORPHENIRAMINE, CYCLOPHOSPHAMIDE, PARACETAMOL, TOCILIZUMAB, ALLOPURINOL

    The George Institute

    Acute lymphoid leukemia

    phase 2 small molecule active

    1 trial

  12. Vebreltinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Potentially Resectable MET-altered Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. Vectibix 20 mg/ml concentrate for solution for infusion, VALPROIC ACID, VALPROIC ACID, Irinotecan Accord 20 mg/ml concentrato per soluzione perinfusione

    Fondazione Telethon ETS

    RAS/BRAF wild-type metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  14. Venclyxto 100 mg film-coated tablets, Azacitidine Kabi 25 mg/mL powder for suspension for injection

    The George Institute

    acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  15. Venclyxto 100 mg film-coated tablets, RITUXIMAB, Calquence 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, RITUXIMAB, Venclyxto 10 mg film-coated tablets

    AstraZeneca AB

    Treatment Naïve Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  16. Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets

    AstraZeneca AB

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    phase 2 small molecule active

    1 trial

  17. Venclyxto 50 mg film-coated tablets, JNJ-54179060, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, IMBRUVICA 140 mg hard capsules

    Janssen-Cilag International N.V.

    Untreated Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  18. Venetoclax

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  19. Venetoclax

    Syndax Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  20. Venetoclax

    The First People's Hospital of Lianyungang

    Acute Leukemia of Ambiguous Lineage

    phase 2 small molecule active

    1 trial

  21. Venetoclax

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  22. Venetoclax

    The First People's Hospital of Lianyungang

    Early T Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  23. Venetoclax monotherapy

    Adaptive Biotechnologies Corp

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule active

    1 trial

  24. Venetoclax, Azacitidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  25. Venetoclax, Azacitidine

    The First People's Hospital of Lianyungang

    T-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  26. Venetoclax, Venetoclax, Acalabrutinib, Venetoclax

    Wuhan Createrna Science and Technology Co., Ltd

    Patients with relapsed CLL, Chronic lymphocytic leukemia

    phase 2 small molecule active

    1 trial

  27. Venetoclax；Azacitidine；Homoharringtonine

    The First People's Hospital of Lianyungang

    Secondary Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  28. Verzenios 50 mg film-coated tablets

    Ningbo Cancer Hospital

    High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy.

    phase 2 small molecule active

    1 trial

  29. Verzenios 50 mg film-coated tablets, TAMOXIFEN

    Eli Lilly Co.

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  30. Verzenios 50 mg film-coated tablets, TEMOZOLOMIDE , IRINOTECAN , Abemaciclib, Abemaciclib

    Eli Lilly Co.

    Ewings Sarcoma

    phase 2 small molecule active

    1 trial

  31. Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer of Biliary Duct

    phase 2 small molecule active

    1 trial

  32. Vidaza 25 mg/ml powder for suspension for injection, Azacitidin STADA 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Azacitidine Mylan 25 mg/mL powder for suspension for injection, Azacitidine Mylan 25 mg/mL powder for suspension for injection, pevonedistat hydrochloride, Venclyxto 100 mg film-coated tablets

    Takeda

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  33. Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)

    phase 2 small molecule active

    1 trial

  34. Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, PIVEKIMAB SUNIRINE, Venclyxto 100 mg film-coated tablets

    AbbVie Deutschland GmbH & Co. KG

    CD123 positive Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  35. Vincristine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Precursor Cell Lymphoblastic Leukemia-Lymphoma

    phase 2 small molecule active

    1 trial

  36. Vinflunine

    United Therapeutics Europe Ltd

    Locally-advanced or Metastatic Penile Neoplasms

    phase 2 small molecule completed

    1 trial

  37. Vitamin D

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  38. Vociprotafib

    Revolution Medicines

    Metastatic Neoplasm

    phase 2 small molecule terminated

    1 trial

  39. Volrustomig

    AstraZeneca

    Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)

    phase 2 mab active

    1 trial

  40. WBRT

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 2 other active

    1 trial

  41. WSD0922-FU, WSD0922-FU

    Alphapharm Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  42. WTX-330

    Werewolf Therapeutics

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    2 trials

  43. Watchful waiting, RO7198457 (autogene cevumeran)

    BioNTech SE

    Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon cancer

    phase 2 small molecule active

    1 trial

  44. Will receive HH-009 injection 20 mg/kg, Q3W

    Huahui Health

    Advanced or Unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  45. X4P-001

    X4 Pharmaceuticals, Inc

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule completed

    2 trials

  46. XB2001 or Placebo

    XBiotech Germany GmbH

    Pancreatic Cancer

    phase 2 mab active

    1 trial

  47. XELOX combined with Fruquintinib and Sintilimab

    The First People's Hospital of Lianyungang

    Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  48. XL092, XL092, XL092, XL092, Belzutifan

    Merck Sharp and Dohme

    Clear cell renal cell carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.